Ferulic acid blocks calcium channels to calm gut contractions
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Toho University researchers (Dr. Keisuke Obara, Dr. Kento Yoshioka, and Professor Yoshio Tanaka of the Faculty of Pharmaceutical Sciences) found that ferulic acid from rice bran reduces intestinal smooth muscle contractions by inhibiting voltage-dependent calcium channels.
- Ferulic acid significantly reduced contractions triggered by acetylcholine, histamine, prostaglandin F2α, and serotonin in guinea pig ileal longitudinal smooth muscle experiments, with the effect being concentration-dependent and reversible.
- The mechanism is noncompetitive — FA did not block the receptors used by those signaling molecules, but instead interfered with a shared calcium-driven contraction pathway in smooth muscle.
- The researchers framed the finding as a potential natural regulator of intestinal motility that could help people with diarrhea-predominant IBS or IBD, while warning the same effect could worsen constipation in healthy individuals or those with constipation-predominant IBS.
- The in vitro concentrations that produced effects exceeded typical blood levels reached through diet, though FA concentrations inside the intestines may be higher after food or supplement intake because the compound contacts the digestive tract directly.
- The study was published in the Journal of Pharmacological Sciences (2025, Vol. 158, Issue 4), with researchers calling for human clinical trials to confirm effects, identify which patients benefit, and determine safe intake levels.
Why it matters: Diarrhea-predominant IBS and IBD patients gain a candidate natural regulator of gut motility, while constipation-prone patients face a genuine risk that the same calming effect worsens their symptoms. The 2025 study is preclinical only — researchers explicitly noted the effective in vitro concentrations exceed normal blood levels, so any dietary or supplement application depends on forthcoming human trials.
